<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858516</url>
  </required_header>
  <id_info>
    <org_study_id>20201101.2</org_study_id>
    <nct_id>NCT04858516</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer</brief_title>
  <official_title>Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in ER-positive, HER2-positive Breast Cancer (neoPEHP): an Exploratory, Open-label, Multi-center Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      neoPEHP is a multicohort, open-label, exploratory, phase 2 study. Patients were eligible if&#xD;
      they had previously untreated, histologically confirmed, unilateral, invasive, HER2-positive,&#xD;
      ER-positive breast cancer and were suitable for neoadjuvant therapy. Patients were treated&#xD;
      every 3 weeks with intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) and&#xD;
      oral pyrotinib (400 mg po QD) for six cycles plus oral palbociclib (125 mg once a day for 21&#xD;
      days in a 4-week cycle) and oral exemestane (25 mg po QD) every 4 weeks for 24 weeks. The&#xD;
      primary endpoints was pathological complete response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response(ypT0/is,ypN0, pCR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>defined as the absence of invasive tumor cells in breast and axilla, ypT0/is ypN0</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palbociclib and exemestane plus trastuzumab and pyrotinib</intervention_name>
    <description>Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib in ER-positive, HER2-positive breast cancer</description>
    <arm_group_label>Neoadjuvant treatment with palbociclib and exemestane plus trastuzumab and pyrotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  We judged patients eligible for the first study cohort if they had previously&#xD;
             untreated, histologically confirmed, unilateral, invasive, HER2-positive (3+ on&#xD;
             immunohistochemistry or neu-amplified) and ER-positive (&gt;10% of cells in the tumour&#xD;
             expressing ER) breast cancer. Other inclusion criteria were age 18 years or older,&#xD;
             Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less, and tumour&#xD;
             classified between cT1c and cT4a-d.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  metastatic disease, bilateral breast cancer, other malignant disease, inadequate bone&#xD;
             marrow or renal function, impaired liver function, impaired cardiac function,&#xD;
             uncontrolled hypertension, pregnancy, and refusal to use contraception.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 18, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

